Stocktoria
VACCINEX, INC. VCNX
OTC · stock · Pharmaceutical Preparations · website · IPO 2018-08-09
VACCINEX, INC. financials (annual, from 10-K)
Bars are annual figures from 2017 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $601,000 | $570,000 | $275,000 | $900,000 | $625,000 | $523,000 | $724,000 | $90,000 |
| R&D expense | $12.5M | $16.6M | $14.0M | $17.2M | $21.5M | $25.7M | $22.4M | $16.6M |
| Operating income | -$18.7M | -$22.9M | -$19.9M | -$22.5M | -$28.3M | -$32.0M | -$27.3M | -$21.1M |
| Interest expense | $2,000 | $1,000 | $2,000 | $809,000 | $489,000 | — | $392,000 | $1.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.6M | -$20.3M | -$19.8M | -$22.4M | -$28.9M | -$31.9M | -$29.5M | -$18.7M |
| EPS (diluted) | $-8.88 | $-43.68 | $-98.05 | $-0.78 | — | — | — | — |
| Operating cash flow | -$16.2M | -$21.4M | -$19.1M | -$25.3M | -$28.6M | -$30.7M | -$25.3M | -$21.4M |
| Free cash flow | -$16.2M | -$21.4M | -$19.2M | -$25.3M | -$28.9M | -$30.8M | -$25.5M | -$21.5M |
| Cash & equivalents | $1.1M | $1.5M | $6.4M | $8.6M | $10.6M | $2.8M | $5.6M | $4.2M |
| Total assets | $2.6M | $3.6M | $8.0M | $9.8M | $11.7M | $4.6M | $22.0M | $5.6M |
| Total liabilities | $5.1M | $5.9M | $2.8M | $2.4M | $14.3M | $6.9M | $6.7M | $7.3M |
| Shareholders' equity | -$2.5M | -$2.3M | $5.2M | $7.4M | -$26.6M | -$26.2M | $15.3M | -$125.5M |
Growth · year-over-year · Revenue CAGR 31.2%
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +5.4% | +107.3% | -69.4% | +44.0% | +19.5% | -27.8% | +704.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001205922 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.